NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...

The US FDA has approved Moderna's next-generation COVID-19 vaccine for adults aged 65 and older, marking a significant stride ...

Robert F. Kennedy Jr. continues his anti-vax crusade by cancelling million-dollar bird flu vaccine deal with Moderna.

THURSDAY, May 29, 2025 (HealthDay News) — The U.S. government has canceled a $600 million contract with Moderna to develop a ...

Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA technology, which is used in the ...

The US Department of Health and Human Services is terminating a contract with drugmaker Moderna to develop a vaccine to ...

The Trump administration has canceled $766 million awarded to Moderna to develop a vaccine against potential pandemic ...

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals ...

The Trump administration has canceled a contract awarded to Moderna for the late-stage development of its bird flu vaccine ...

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.